drugset / Trial / NCT07215520
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
Timeline
- Start
- 2025-11-03
- Primary completion
- 2026-08-19
- Completion
- 2026-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NDV-HXP-S-KP.2 | Vaccine | — | Intranasal |